Comparing Prednisone and Methotrexate to Off-label Biologic Infliximab for Management of Ocular Uveitis: A Cost-minimization Analysis
**Background:** Approximately 3.75% of cases of blindness in the United States are caused by uveitis. Incurred clinical costs and lost productivity related to vision loss in these cases totals $3.58 billion annually. **Objective:** To evaluate whether infliximab, a modern off-label biologic, is cos...
Saved in:
Main Authors: | William V. Padula, Miguel Cordero-Coma, Taygan Yilmaz, Michéal J. Gallagher, Jonathan D. Campbell |
---|---|
Format: | Article |
Language: | English |
Published: |
Columbia Data Analytics, LLC
2015-01-01
|
Series: | Journal of Health Economics and Outcomes Research |
Online Access: | https://doi.org/10.36469/9895 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
The Effectiveness of Intraocular Methotrexate in the Treatment of Posterior Uveitis in Behçet’s Disease Patients Compared to Retrobulbar Steroids Injection
by: Hossam El Din Mohamed Khalil, et al.
Published: (2016-01-01) -
The Effectiveness of Pre- and Postoperative Infliximab in Controlling Behçet’s Disease Posterior Uveitis in Patients Undergoing Vitrectomy: A Preliminary Study
by: Hossam El Din Mohamed Khalil, et al.
Published: (2017-01-01) -
Levothyroxine and Prednisone Causing Generalized Weakness in a Middle-Aged Man
by: Andrew Word, et al.
Published: (2012-01-01) -
Think Stop before Going 'Off-Label'
by: Gerald Y Minuk
Published: (2004-01-01) -
Prednisone inhibits osteosarcoma cell by regulating the Wnt/β-catenin signaling pathway
by: Yo Zhang, et al.
Published: (2024-12-01)